Search Results
Your search for ,ArM matches 4692 pages
Showing 4451 - 4500Patients With Incomplete Response to Neoadjuvant Chemotherapy Benefit From Capecitabine
Treatment with capecitabine increased disease-free and overall survival in breast cancer patients with residual disease after neoadjuvant chemotherapy, according to a study reported by researchers from Japan and Korea at the 2015 San Antonio Breast Cancer Symposium.1 “It has been unclear whether...
FDA Expands Pembrolizumab Label to Include Approval in Initial Treatment of Unresectable or Metastatic Melanoma
On December 18, 2015, the U.S. Food and Drug Administration (FDA) expanded the pembrolizumab (Keytruda) label to include approval of the drug for the treatment of patients with unresectable or metastatic melanoma. This expansion now includes the initial treatment of patients with unresectable or...
FDA Approves Alectinib for Advanced ALK-Positive NSCLC
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to alectinib (Alecensa) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) who have had disease progression on or are intolerant to crizotinib (Xalkori). ...
Homologous Recombination Deficiency Diagnostic Test Helps Identify Patients With Breast Cancer Likely to Respond to Platinum-Based Therapy
Two studies evaluating the ability of myChoice HRD, a homologous recombination deficiency (HRD) test, to identify patients with breast cancer who are likely to respond to platinum-containing therapies have found that the test is effective in optimizing therapy selection for patients. The diagnostic ...
FDA Approves Uridine Triacetate for Emergency Treatment of Fluorouracil or Capecitabine Overdose
The U.S. Food and Drug Administration (FDA) today approved uridine triacetate (Vistogard) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil (5-FU) or capecitabine, or who develop certain severe or life-threatening toxicities within...
SABCS 2015: Pathologic Complete Response to Presurgery Chemotherapy Improves Survival for Patients With Triple-Negative Breast Cancer
Patients with stage II or stage III triple-negative breast cancer who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more than minimal residual invasive disease at surgery following presurgery...
Improved Overall Survival With Addition of Nanoliposomal Irinotecan to Fluorouracil/Leucovorin in Metastatic Pancreatic Cancer
In the phase III NAPOLI-1 trial reported in The Lancet, Wang-Gillam et al found that the addition of nanoliposomal irinotecan (Onivyde) to fluorouracil (5-FU) and folinic acid (leucovorin) resulted in improved overall survival in patients with metastatic pancreatic ductal cancer who had received...
ASH 2015: Young Adults With Acute Lymphoblastic Leukemia Have Encouraging Survival With Pediatric Chemotherapy Regimen
Using a pediatric chemotherapy regimen to treat young adults with acute lymphoblastic leukemia (ALL) significantly improved their outcomes compared to what has historically been achieved with “adult” treatment protocols, report Dana-Farber Cancer Institute scientists. Overall survival...
ASH 2015: Updated Results of Phase III Tourmaline-MM1 Study of Ixazomib in Multiple Myeloma
In a study presented by Moureau et al at the 57th American Society of Hematology (ASH) Annual Meeting, ixazomib (Ninlaro), a recently approved oral proteasome inhibitor, significantly extended progression-free survival for patients with relapsed and/or refractory multiple myeloma (Abstract 727)....
ASH 2015: Combination Therapy With Idelalisib Improves Progression-Free Survival vs Bendamustine/Rituximab Alone in Relapsed/Refractory CLL
In a phase III study to be presented by Zelenetz et al at the 57th American Society of Hematology Annual Meeting, idelalisib (Zydelig) plus bendamustine (Treanda) and rituximab (Rituxan), or BR, proved superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)...
ASH 2015: Adding Rituximab to Standard Chemotherapy in CD20-Positive Philadelphia Chromosome–Negative BCP-ALL Improves Event-Free Survival
The results of the randomized Graall-R 2005 study presented by Maury et al at the 57th American Society of Hematology (ASH) Annual Meeting found a new use for rituximab (Rituxan) in acute leukemia (Abstract 1). CD20 is present in 30% to 50% of patients with B-cell precursor acute lymphocytic...
ASH 2015: Midostaurin Improves Survival in Patients With FLT3-Mutated Acute Myeloid Leukemia Aged 18–60
A study presented by Stone et al at the 57th American Society of Hematology (ASH) Annual Meeting described a phase III trial of the first targeted therapy for genetically defined subset of patients with acute myeloid leukemia and its improvement of their survival (Abstract 6). Acute myeloid...
FDA Approves Single-Agent Nivolumab for Previously Untreated BRAF Wild-Type Advanced Melanoma
The U.S. Food and Drug Administration (FDA) today approved the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) as a single agent for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Clinical Trial Results The approval is based on data...
FDA Approves Necitumumab Combination for Metastatic Squamous NSCLC
The U.S. Food and Drug Administration today approved necitumumab (Portrazza) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of nonsquamous NSCLC....
FDA Approves Osimertinib for EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer After Progression on Prior EGFR-Blocking Therapy
The U.S. Food and Drug Administration (FDA) granted accelerated approval for an oral medication to treat patients with advanced non–small cell lung cancer (NSCLC). Osimertinib (Tagrisso) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation ...
Improved Outcomes With Modified Docetaxel, Cisplatin, and 5-FU vs Standard Regimen Plus Growth Factor Support in Metastatic Gastric Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Shah et al in the U.S. Gastric Cancer Consortium found that a modified regimen of docetaxel, cisplatin, and fluorouracil (5-FU) (mDCF) improved toxicity and survival vs a standard DCF regimen plus growth factor support as first-line...
6-Year Incidence of Cardiac Events in NCCTG N9831/Alliance Adjuvant Trastuzumab Trial
As reported in the Journal of Clinical Oncology by Advani et al, the cumulative incidence of cardiac events remained significantly higher at 6 years in breast cancer patients who received adjuvant trastuzumab (Herceptin) in the NCCTG N9831/Alliance trial. However, few new congestive heart failure...
Telotristat Etiprate Shows Clinical Benefit in Treating Carcinoid Syndrome in Cancer Patients When Added to Standard of Care
Lexicon Pharmaceuticals, Inc's telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, according to data from the phase III TELESTAR study presented...
FDA Approves Talimogene Laherparepvec for Unresectable Recurrent Melanoma
The U.S. Food and Drug Administration (FDA) has approved the biologics license application for talimogene laherparepvec (Imlygic), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma...
FDA Approves Liposomal Irinotecan for Advanced Pancreatic Cancer
The U.S. Food and Drug Administration today approved irinotecan liposome injection (Onivyde), in combination with fluorouracil (5-FU) and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. According to the National...
ASTRO 2015: Patients With Bone Metastases Undergoing Radiation Therapy for Symptom Control Have Lower Pain Flare Rates With Steroid Use
The steroid dexamethasone reduces radiation-induced pain flare in cancer patients with painful bone metastases, according to research presented by Chow et al (Abstract LBA1) October 18, 2015 at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting in San Antonio,...
More Than 11 Moles on the Arm May Indicate Higher Risk of Melanoma
Researchers at King's College London have investigated a new method that could be used by general practitioners to quickly determine the number of moles on the entire body by counting the number found on a smaller “proxy” body area, such as an arm. These findings were published by...
ECC 2015: Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma: Results of the IMvigor 210 Study
At the 2015 European Cancer Congress in Vienna, Austria, early results were announced (Abstract 21LBA) from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy atezolizumab (anti–PD-L1; MPDL3280A) in people with locally advanced or metastatic urothelial...
FDA Grants Accelerated Approval to Nivolumab in Combination With Ipilimumab in BRAF V600 Wild-Type, Unresectable, or Metastatic Melanoma
On September 30, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the treatment of patients with BRAF V600 wild-type, unresectable, or metastatic melanoma. The FDA is scheduled to make a decision on ...
ECC 2015: Cabozantinib Improves Survival in Patients With Advanced Kidney Cancer
Patients with advanced kidney cancer lived for nearly twice as long without their disease progressing if they were treated with cabozantinib (Cometriq), a drug that inhibits the action of tyrosine kinases. Toni Choueiri, MD, presented the research (Abstract 4LBA) at the Presidential Session of the...
Adding Lenalidomide to Melphalan/Prednisone Yields Better Quality of Life Than Thalidomide in Elderly Patients With Multiple Myeloma
A phase III Eastern Cooperative Oncology Group (ECOG) trial (E1A060) comparing melphalan, prednisone, and thalidomide (Thalomid) (MPT-T) with melphalan, prednisone, and lenalidomide (Revlimid) (mPR-R) in elderly patients with untreated multiple myeloma found that at the end of the induction period, ...
WCLC: Adding Bevacizumab to Chemotherapy Does Not Improve Overall Survival in Early-Stage NSCLC
Adding the monoclonal antibody bevacizumab (Avastin) to chemotherapy for patients with surgically removed non–small cell lung cancer (NSCLC) did not improve overall survival, according to research (Abstract PLEN04.03) presented at the 16th World Conference on Lung Cancer (WCLC) in Denver,...
New Agent Targeting Epigenetic Modifications Shows Activity in Advanced Cancer
In a dose-escalation phase I study reported in The Lancet Oncology, Reid et al found that RRx-001, a representative of a new class of compounds called dinitroazetidines (sourced from the aerospace industry) that act on the tumor microenvironment, had activity in advanced cancers and a promising...
WCLC: Results From ROMANA Trials of Anamorelin in Advanced NSCLC Patients With Cachexia
Two phase III studies of anamorelin found that the medication effectively combats wasting and increases body weight and lean body mass in certain patients with lung cancer. Results (Abstract ORAL29.01) from the ROMANA 1 and ROMANA 2 phase III trials of anamorelin were presented at the 16th...
WCLC: Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma
The standard of care for malignant pleural mesothelioma may be poised for change, judging by results from a study (Abstract ORAL11.01) by the French Cooperative Thoracic Intergroup. The addition of bevacizumab (Avastin) in the first-line setting to the current standard of care, pemetrexed...
Phase II Trial Shows Greater Activity With Lenalidomide/Rituximab vs Lenalidomide in Recurrent Follicular Lymphoma
In a phase II trial (Cancer and Leukemia Group B 50401/Alliance) reported in the Journal of Clinical Oncology, Leonard et al found that the addition of rituximab (Rituxan) to lenalidomide (Revlimid) produced a higher response rate and longer time to progression than lenalidomide alone in patients...
Adjuvant Taxane-Based Chemotherapy Is Not Associated With Increased Risk of Lymphedema, Study Finds
In women with breast cancer, taxane-based chemotherapy—docetaxel and paclitaxel—did not appear to increase the incidence of lymphedema, according to a study by Swaroop et al in Breast Cancer Research and Treatment. However, the investigators did note that adjuvant chemotherapy with...
ASCO Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
As reported by Schnipper et al in the Journal of Clinical Oncology, the ASCO Value in Cancer Care Task Force has released an ASCO statement detailing a conceptual framework to assess the value of cancer treatment options. The aim of ASCO in developing the framework is to encourage more...
FDA Grants Breakthrough Therapy Designation to Lenvatinib for Metastatic Renal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) granted lenvatinib (Lenvima) Breakthrough Therapy designation for investigational use in patients with advanced or metastatic renal cell carcinoma who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy. Lenvatinib...
FDA Approves Carfilzomib Combination for Patients With Relapsed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved carfilzomib (Kyprolis) in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The approval was based on a demonstration of ...
FDA Approves Sonidegib for Locally Advanced Basal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) approved sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy. The approval was based on...
FDA Approves Gefitinib for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved gefitinib (Iressa) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an...
ESMO World GI 2015: Second-Line Cetuximab Active Beyond Progression in Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer that are free of mutations in the KRAS, NRAS, BRAF, and PIK3CA genes showed a significant benefit from continuing antiepidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody. ...
Better Outcome With Paclitaxel vs Nab-Paclitaxel or Ixabepilone Plus Bevacizumab in First-Line Treatment of Advanced Breast Cancer
In the phase III CALGB 40502/NCCTG N063H/Alliance trial reported in the Journal of Clinical Oncology, Rugo et al found that outcomes in first-line treatment for advanced breast cancer were better with weekly paclitaxel plus bevacizumab (Avastin) compared with weekly nanoparticle albumin-bound...
Latest RTOG 0537 Data Indicate Electrical Nerve Stimulation May Provide Relief for Radiation-Induced Dry Mouth
Phase III results of Radiation Therapy Oncology Group (RTOG) 0537 indicate that acupuncture-like, transcutaneous electrical nerve stimulation (ALTENS) may be equally effective as the prescription medication pilocarpine, the current standard of care, to treat radiation-induced xerostomia (dry...
ASCO 2015: Study Supports IDH Gene as Prognostic Marker in Anaplastic Astrocytoma
New findings from a phase III clinical trial suggest the IDH1 gene may be a prognostic marker for anaplastic astrocytoma, a rare form of brain cancer. The results of this study were presented on June 2 at the 2015 ASCO Annual Meeting in Chicago (Abstract 2002). Patients in this study who had a...
ASCO 2015: Novel Targeted Drug Palbociclib Slows Progression of Hormone Receptor–Positive Breast Cancer
Results from the phase III registration study PALOMA-3 show that adding the investigational targeted agent palbociclib (Ibrance) to the standard hormonal therapy fulvestrant (Faslodex) more than doubled the duration of disease control, delaying disease progression by roughly 5 months in women with...
ASCO 2015: NCI-MATCH Trial Links Targeted Drugs to Genetic Abnormalities
Investigators for the nationwide trial NCI-MATCH: Molecular Analysis for Therapy Choice announced at the 2015 ASCO Annual Meeting in Chicago that the precision medicine trial will open to patient enrollment in July. The trial seeks to determine whether targeted therapies for people whose tumors...
ASCO 2015: Investigational ALK Inhibitor Demonstrates Promising Overall Response Rates in Patients With Advanced ALK-Positive NSCLC
The oral investigational anaplastic lymphoma kinase (ALK) inhibitor alectinib shrank tumors in almost half of patients with advanced ALK-positive non–small cell lung cancer (NSCLC) whose disease had progressed following crizotinib (Xalkori) treatment. Positive results from two clinical...
ASCO 2015: Phase III Study Confirms Benefits of Lenalidomide Maintenance Therapy for Patients With Multiple Myeloma
A large, cooperative group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide (Revlimid) delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with this rare but...
ASCO 2015: JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis
Findings from the PERSIST-1 study of patients with myelofibrosis show that the JAK inhibitor pacritinib is significantly more effective than best available therapy, which includes a range of off-label treatments, for easing the symptoms of myelofibrosis. At a landmark analysis at 24 weeks of...
ASCO 2015: Obinutuzumab Doubles Progression-Free Survival in Patients With Relapsed, Indolent Non-Hodgkin Lymphoma
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard bendamustine (Treanda) chemotherapy and then following that with single-agent obinutuzumab maintenance therapy “resulted in a statistically significant, but more importantly, a clinically meaningful increase in...
ASCO 2015: Adding Chemotherapy to Initial Therapy Improves Survival in Patients With Advanced, Hormone-Naive Prostate Cancer
The UK-led STAMPEDE trial found that adding docetaxel chemotherapy to standard hormone therapy markedly improved survival for men with newly diagnosed advanced prostate cancer not previously treated with hormone therapy (hormone-naive). Men who received docetaxel plus standard therapy lived on...
ASCO 2015: Adding Elotuzumab Significantly Reduces Risk of Progression for Relapsed Multiple Myeloma
Interim results of a phase III trial suggest an innovative immune-based therapy may offer a new option for patients with relapsed multiple myeloma. The new monoclonal antibody elotuzumab, added to standard lenalidomide (Revlimid) and dexamethasone therapy, extended the duration of remissions by...
Targeted Massively Parallel Sequencing Study Indicates Similarity of Somatic Driver Mutations in NSCLC for African American vs European Ancestry
In a study reported in the Journal of Clinical Oncology, Araujo et al used targeted massively parallel sequencing to produce an in-depth molecular profile of non–small cell lung cancer (NSCLC) in African Americans. Comparison with findings in patients of European/white ancestry with NSCLC...
